Search This Blog

Wednesday, October 23, 2013

FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer (NYSE:LLY)

FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.